pharmaceuticals

pharmaceuticals Articles

Johnson & Johnson is looking to save some money over the next few years and as a result it is taking action by restructuring its Medical Devices businesses.
These biotech companies stood out from the rest with big moves over the course of the past week.
These companies are well along in clinical trials and some are close to presenting Phase 3 results. Sticking with industry leaders always makes sense in a very volatile sector.
The short interest data have been released for the December 31 settlement date. For most of the selected pharmaceutical stocks short interest was up.
Beigene has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Anavex Life Sciences was one of the stocks helping to prop up the market in Monday’s session.
Clearside Biomedical has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
A new RBC report focuses on top biotech stocks with key data readouts coming in 2016. These three seem to be the farthest along and offer the best chance for approval.
Ardelyx recently filed with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering.
One good plan for stockholders who are seeing gains evaporate is to rotate to a more defensive sector. Large cap pharmaceutical stocks totally fit the bill.
Collegium Pharmaceutical has filed with the U.S. Securities and Exchange Commission (SEC) regarding its secondary offering.
This is going to be a big year in biotech, with a host of drugs set to undergo FDA scrutiny. These four companies with promising candidates all have dates with the agency this year.
Dynavax Technologies led the bulls on Thursday with positive results from a late stage clinical trial, on another consecutive down day for the broad markets.
Mapi Pharma has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Spring Bank Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).